Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airfl ow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fi xed-dose combinations (FDC) with longacting ␤2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with signifi cant numbers given ICS/LABA as fi rstline maintenance therapy. The role of ICS in the treatment paradigm for COPD is changing, driven by the growing evidence of increased risk of pneumonia, and the introduction of a new class of FDC; LABA and long-acting muscarinic antagonists (LAMA), which simplify dual bronchodilation and present a plausible alternative therapy. As the evidence base for dual therapy bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm and ICS reserved for those with more severe disease who are not controlled on dual therapy. This change has already manifested in local COPD algorithms, such as those at Tayside, and represents a signifi cant change in recommended prescribing practice. This review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.
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Introduction
Important changes in our perspective and understanding of chronic obstructive pulmonary disease (COPD) have led to marked improvements in the treatment approach (1) . Disease management has moved beyond spirometric parameters to include patient centred outcomes such as dyspnoea and exacerbation frequency, which are recognised as important elements in the assessment of treatment eff ectiveness, and there is acknowledgment of the importance of COPD phenotyping in optimising therapeutic options. In 2013, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued an updated document detailing the classifi cation and treatment of COPD (1) . GOLD recommends classifying patients into one of four risk groups (A-D) using a combination of spirometry, symptoms and risk of future exacerbations. Treatment algorithms were suggested for each group, however bronchodilator therapy has remained the cornerstone of pharmacological management in all groups. Indeed, long-acting muscarinic antagonists (LAMA) are a fi rst-line treatment option for any but those with mildest disease. GOLD suggests considering the use of inhaled corticosteroids (ICS) in patients with severe airfl ow limitation or for those who are at high risk of exacerbations. Th is is based on evidence demonstrating that ICS, especially when prescribed in fi xed-dose combinations (FDC) with long-acting β 2 agonists (LABA), improve quality of life (QoL), decrease exacerbations, hospitalisations (2) , and have been associated with a trend towards a reduction in all-cause mortality (3) . Dual bronchodilation, through co-prescribing of LABA and LAMA, could be an alternative to ICS/LABA in certain COPD phenotypes. Also this approach could be used particularly in patients who remain symptomatic after LABA monotherapy, but who cannot tolerate or do not wish to take ICS. Th is concept, however, is not given the prominence it merits in the new GOLD, (1) or indeed other, guidance (1, 4) .
Th e pivotal study which showed benefi ts of ICS/ LABA, recruited participants with a forced expiratory volume in one second (FEV 1 ) of less than 60% predicted (3) . Th ere is no evidence supporting the therapeutic benefi t of ICS/LABA in COPD patients with less severe airfl ow limitation, irrespective of exacerbation history (5) . Despite this, ICS prescribing patterns demonstrate far wider application in COPD pharmacotherapy than recommended, with ICS/LABA a widely prescribed maintenance drug. Audit shows that routine prescribing practice frequently uses inhaled therapies outside current guideline recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with signifi cant numbers given ICS/ LABA as fi rst-line drug (6) . Th is prescribing pattern may refl ect the familiarity of prescribing ICS/LABA including historical prescribing where drug therapy is maintained because of disease stability, but it may also be a manifestation of physician concerns over the accuracy of diagnosis of COPD versus asthma resulting in continued ICS/LABA use.
Th e breadth of prescribing of ICS in COPD and lack of effi cacy data in individuals with a FEV 1 > 60% highlights the need for the risk-benefi t profi le of ICS to be considered closely. ICS/LABA combinations are associated with a number of side eff ects beyond the topical eff ects of oral candidiasis and dysphonia, the most serious of which is an increased incidence of pneumonia (7) . Randomised controlled trials and observational studies have persistently described the risk of pneumonia associated with ICS use, especially with fl uticasone (3, 8) . It has been suggested that there is an intra-class diff erence in ICS with respect to the risk of pneumonia; however, this is not a consistent observation (9) . In addition, recent clinical trial data has suggested that the pneumonia extends to a new ICS currently in development (10, 11) .
Th e evidence base for the effi cacy and safety of dual bronchodilation has been limited until now (12) . However the evidence for new LABA/LAMA FDC suggests a greater effi cacy than LABA or LAMA monotherapy (13) . Th is greater effi cacy has been shown over a diverse range of clinically relevant outcomes, and identifi es LABA/LAMA FDC as a potential new treatment option when trying to maximise symptom control and reduce exacerbations. Th is review reassesses the role of ICS in the shifting treatment paradigm, in the context of alternative treatment options that provide maximal bronchodilation.
Review
Inhaled corticosteroids in chronic obstructive pulmonary disease Th irty years ago, ICS were established as eff ective treatments to reduce morbidity and mortality in asthma patients (14) . Th is success prompted research into its possible therapeutic role in COPD, although initial evidence of effi cacy was limited. Th e randomised controlled trials of ICS in COPD which followed in the 1990's had mixed results. Th ere was no improvement in the rate of decline in lung function or exacerbation frequency when compared with placebo in studies of 6 months to 3 years duration (5, (15) (16) (17) (18) (19) . It was not until ISOLDE (20) ; the fi rst large, long-term, randomised, doubleblind, placebo-controlled trial of ICS, that reduction in exacerbation rates and health care utilisation of ICS as therapy was described. From this point on, clinical trials analyses (2, 26 (20) . In a pooled analysis of 5601 participants from 6 studies with predominantly poorly reversible, severe COPD, the use of ICS/LABA FDC signifi cantly reduced exacerbation rates (rate-ratio 0.87, 95% CI 0.80 to 0.94) compared with ICS alone (26) .
In terms of lung function and QoL, post-hoc analyses of TORCH reported an adjusted rate of decline in FEV 1 of 55 mL/year for placebo, 42 mL/year with FP or SAL, and for the combination of drugs a 39 mL per year decline, suggesting that treatment with ICS, LABA or the combination of two, can slow FEV 1 decline (27) . Th e Cochrane analysis reported a pooled diff erence in rate of decline of post-bronchodilator FEV 1 of 6.88 mL/year (95% CI 1.80 to 11.96, 5 studies, 4823 participants) in favour of ICS (2) . TORCH reported an improvement with SFC of 3.0 units of the St Georges Respiratory Questionnaire (SGRQ) compared to baseline after 3 years of treatment (p < 0.001 vs. placebo), with an improvement of 1.8 units in the fl uticasone group (p < 0.001 vs. placebo); the placebo group showed a deterioration of 0.2 units in the SGRQ. Th e eff ect was largest in more severe COPD-an improvement in SGRQ of 5.9 units with combination therapy in stage 4, and 3.3 units with GOLD stage 3; in stage 2, the SGRQ improvement was less (2.3 units), but still signifi cant (3). Despite these positive fi ndings, the prescribing of ICS for COPD has remained a controversial subject (28, 29) Safety profi le of ICS treatment Th e side eff ects of ICS treatment range from frequent unpleasant local side eff ects, such as oral candidiasis and dysphonia (2) , to less common ones, such as adrenal suppression (30) , cataracts (31, 32) , and pneumonia (3, 8, (32) (33) (34) (35) . Th e side eff ect profi le potentially extends to include osteoporotic fractures (2, 36) and increased diabetes risk (37, 38) .
Th e studies of osteoporosis and fracture risk include combinations of randomised controlled trials and observational studies, each of which employed diff erent defi nitions and therefore should be interpreted with caution. Several meta-analyses have reported confl icting results; Loke and colleagues found a modest but statistically signifi cant increased likelihood of fractures in those treated with ICS (36); however, a Cochrane review reported that long-term studies which measured bone eff ects generally showed no major eff ect on fractures and bone mineral density over 3 years of follow-up (2) .
Systemic corticosteroids are known to increase diabetes risk, but the impact of ICS is less well characterised. A large population based study of 388,584 patients with respiratory disease found treatment with ICS was focused on assessing ICS/LABA combinations as well as ICS and LABA as monotherapy.
TRISTAN was one of the fi rst, large (N = 1465), double-blind, randomised studies, which compared twicedaily salmeterol/fl uticasone propionate 50/500 μg (SFC) to salmeterol 50 μg (SAL), fl uticasone propionate 500 μg (FP) or placebo (21) . Although the primary endpoint was pre-bronchodilator FEV 1 , the number of exacerbations was an important secondary endpoint assessed at every clinic visit. All therapies improved lung function, symptoms, health status and reduced use of rescue medication and frequency of exacerbations compared to placebo; however combination therapy with SFC was more eff ective than salmeterol alone. Th e treatment eff ect was most pronounced in severe disease; those with a baseline FEV 1 < 50% showed a 30% reduction in exacerbation frequency with SFC compared to placebo, whereas there was only a 10% reduction in those patients whose FEV 1 > 50%.
Th e seminal TORCH trial (Towards a Revolution in COPD Health) followed several years later; this randomised 6112 patients to SFC (100/1000 μg/day), SAL (100 μg/day), FP (1000 μg/day) or placebo (3). All-cause mortality was the primary endpoint, with lung function, exacerbations and QoL reported over a period of 3 years. Th e SFC treatment group demonstrated, a 25% reduction in the annual rate of exacerbations (0.85 (95% CI, 0.80 to 0.90)) compared to placebo (1.13 (95% CI, 1.07 to 1.20)), with a number needed to treat (NNT) of four to prevent one exacerbation. At the same time, Kardos and colleagues compared SFC with SAL monotherapy in 994 patients with severe COPD for around 4 years (22) . Combination therapy with SFC reduced the total number of exacerbations (334 vs. 464, p < 0.0001), the annual rate of moderate/severe exacerbations (0.92 vs. 1.4, corresponding to a 35% decrease, p < 0.0001) and the mean time to fi rst exacerbation (128 vs. 93 days, p < 0.0001) (22) .
A signifi cant limitation of the studies described above is that they recruited patients based at least in part on an arbitrary FEV 1 cut off rather than the underlying phenotype ie emphysema or chronic bronchitis; it is well established that ICS will have benefi cial eff ects in those with predominantly moderate degrees of airway obstruction and airway hyperresponsiveness or modest reversibility of FEV 1 (23) . A lack of phenotyping is also present when it comes to exacerbations, many of the studies looking into the usefulness of ICS tend to simply group all exacerbations together, however this may limit a study's power to demonstrate ICS eff ectiveness. COPD exacerbations can be very diff erent: infective (viral and/or bacterial), eosinophilic predominant or pauci-infl ammatory (24) . Th ere is evidence that different treatments can be eff ectively adopted to reduce diff erent COPD exacerbations, for instance, ICS added to long-acting bronchodilators can be utilised eff ectively to avoid eosinophilic exacerbations (25) .
Summary evidence of the eff ect of ICS on COPD exacerbations is provided from recent Cochrane meta-www.tandfonline.com/icop associated with a 34% (RR 1.34 (95% CI 1.29-1.39)) increased risk of new onset diabetes (defi ned by initiation of an oral hypoglycaemic agent), with the highest dose associated with the greatest risk (37) . More recently, a retrospective study of administrative claims data from the Australian Government Department of Veterans' Aff airs of more than 18,000 patients with diabetes, found there to be an increased risk of diabetesrelated hospitalisations with the use of high-dose ICS (38) . However, it is the increased risk of pneumonia which represents the greatest concern in regards to the use of ICS in COPD management.
ICS and pneumonia risk
Patients with COPD are at an increased risk of pneumonia due to the nature of the disease itself and risks may be further increased with ICS use. TORCH showed an increased rate of pneumonia among all patients receiving treatment containing ICS, with a two-fold higher rate of pneumonia compared with patients in the placebo arm (3), with a number-needed-to-harm (NNH) of 17 (33) . A subsequent analysis of the TORCH data showed that the risk factors for ICS-associated pneumonia were increasing age, worsening spirometry, a history of COPD exacerbations in the year prior to the study, worse Medical Research Council (MRC) dyspnoea scores and a low body mass index; thus not dissimilar to the usual risk factors for pneumonia (39) . Th e subsequent INSPIRE study (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) comparing salmeterol plus fl uticasone propionate 50/500 μg twice daily with tiotropium 18 μg once daily, reported double the rate of pneumonia with SFC (8%) than with tiotropium (4%) (34) . Th e evidence of a dose-response for pneumonia risk comes from a nested case-control study of 175,906 patients, which found that the highest doses of ICS were associated with the highest rate-ratio for hospitalisation (rate-ratio of 2.25) (35) . Summary evidence of the risk is provided by a Cochrane meta-analysis of 14 studies combining 11,794 patients, which reported moderatelevel evidence of an increased pneumonia risk (by 50%) with ICS/LABA combinations versus LABA alone; however, mortality was identical between the treatment groups (23) .
Randomised controlled studies of new agents currently in clinical development have also reported pneumonia. ILLUMINATE, a double-blind, double-dummy trial in 523 patients with GOLD stages II and III, without exacerbations in the previous year, compared once-daily LABA/LAMA FDC (QVA149 110/50 μg) or twice-daily SFC 50/500 μg for 26 weeks (40). Radiologically confi rmed pneumonia was only reported in the SFC treatment group (four patients; 1·5%). A new ICS/LABA FDC, recently approved by the United States Food and Drug Administration (FDA) for the treatment of COPD-fl uticasone furoate/vilanterol (FF/VI)-was assessed for exacerbation prevention in COPD patients with a history of exacerbations in two replicate, phase III randomised double-blind trials of 1622 patients (10) . Th ree doses of fl uticasone furoate were used (50 μg, 100 μg, and 200 μg) in combination with vilanterol 25 μg. Pneumonia and fractures were reported more frequently with FF/VI than with vilanterol alone. Eight deaths from pneumonia in the FF/VI groups compared with none in the vilanterol only group prompted discussion highlighting that the safety of ICS in COPD is a serious problem (11) . Th e study was not powered to look at diff erences in pneumonia-specifi c mortality and overall mortality was not signifi cantly diff erent between the two groups. Interpreting the excess pneumonic episodes is complicated by the fact that ICS/LABA use in COPD decreases the rate of exacerbations and hospitalisations in clinical studies, and that no pneumonia deaths were identifi ed secondary to SFC in TORCH (39) . Reassuringly, a study looking at the impact of ICS use on outcome in COPD patients admitted with pneumonia did not show an association with worse mortality or the development of complications (41) .
It has been suggested that ICS type may infl uence the risk, with some studies such as PATHOS suggesting that fl uticasone carries a higher risk than others such as budesonide (8, 42) . In this observational, retrospective cohort study, budesonide/formoterol or SFC were compared for pneumonia event rates, admission to hospital related to pneumonia, and mortality associated with pneumonia. SFC patients were signifi cantly more likely to experience pneumonia and had a higher mortality related to pneumonia than patients treated with budesonide/formoterol. Th e authors off ered plausible explanations for the observed diff erence, suggesting that the known immunosuppressant potency of fl uticasone (10-fold higher than that of budesonide with regard to ex vivo inhibition of human alveolar macrophage innate immune response to bacterial triggers) could explain the fi ndings. It must be noted that this was an observational study and that other studies of budesonide and mometasone in COPD have shown an increased rate of pneumonia associated with use of these agents (9, 43) . Th e defi nitive answer as to whether this phenomenon is a class eff ect or one specifi c to fl uticasone remains unclear.
ICS prescribing patterns ICS's important but targeted role in COPD treatment
is not refl ected in prescribing patterns. In a large Italian study investigating whether pulmonologists follow GOLD recommendations when prescribing treatment for COPD, ICS alone and ICS/LABA combinations were over-prescribed in GOLD stages I and II, in patients without exacerbations in 40% and 64%, respectively. Overall, 62.1% of prescribing was not in keeping with GOLD recommendations (44) . Similar fi ndings were described in a French study, which found that more than half of all patients in GOLD class I and II were prescribed ICS (45) .
Tayside Allergy and Respiratory Disease Information System (TARDIS) is a structured management Table 1 . COPD treatment algorithm employed by NHS Tayside. The algorithm recommends that a combined inhaled steroid and long-acting bronchodilator should be prescribed only if the patient has persistent breathlessness or repeated exacerbations despite optimal bronchodilator therapy (defi ned in step 3 as LABA and LAMA co-prescribing, coloured blue) and should be discontinued if no benefi t after 4 weeks
Symptoms
Inhaled Medication 1
Step 1 Breathlessness and exercise limitation SABA or SAMA as required
Step (4) . According to GOLD, ICS/LABA is appropriate for patients with GOLD FEV 1 < 50% or in those at high risk of future exacerbations (1) .
Clearly, ICS/LABA remains a valuable treatment option for selected patients with severe COPD or frequent exacerbations, however, phenotyping individuals to direct ICS therapy to those most likely to benefi t is an important aim. As described above, COPD is a heterogeneous disease with clinically relevant phenotypes and these emerging phenotypes must be considered when planning therapeutic intervention. For example there is probably small benefi t of prescribing high dose ICS to a COPD patient with predominant emphysema especially in the presence of relatively little airfl ow limitation while potentially exposing the individual to the risk of well recognized adverse side eff ects while at the same time ICS may potentially be used benefi cially albeit without strict licensing criteria in non-smokers or ex-smokers with a relatively preserved FEV 1 but with symptoms secondary to recurrent eosinophilic COPD exacerbations.
Despite this, the current possibility of guideline concordant ICS prescription irrespective of FEV 1 moves ahead of the evidence, as the proven benefi t of ICS is restricted to those with more severe airfl ow restriction. Th is is sustained in the opinion of the Scottish Medicines Consortium, which has restricted the license of ICS/LABA to individuals with a FEV 1 <50% (48) . With emerging data on LABA and LAMA co-prescribing, both as free agents and FDC, the recommendation to consider dual bronchodilation only if ICS prescribing is not appropriate, will need to be altered in future guidelines. Important questions for guideline development groups to address will include establishing the role of dual bronchodilation in treatment algorithms in relation to ICS/LABA. Th is will involve only identifying which patients are most likely to benefi t from dual bronchodilation and also taking into account factors such as risk and impact of side eff ects, symptoms and patient preference.
Subtle changes to the COPD guideline in Tayside were recently introduced to refl ect current treatment options. ICS/LABA FDC are still recommended for persistent breathlessness or repeated exacerbations despite bronchodilator therapy (see step 4 in Table 1 ) with the proviso that ICS/LABA should only be prescribed if there are persistent symptoms and/or exacerbations despite maximal bronchodilator therapy (defi ned as co-prescribing of LABA and LAMA). In essence, LABA and LAMA co-prescribing has been 'pulled up' the treatment algorithm ahead of ICS/LABA, encouraging prescribing of ICS in patients with the most severe disease.
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Combining LABA and LAMA in COPD Th e rationale for co-prescribing of LABA and LAMA is clear; combining long-acting bronchodilators with distinct, complementary and possibly synergistic mechanisms of action, has the potential to maximise bronchodilator response. Muscarinic receptor antagonists inhibit bronchoconstriction by inhibiting the binding of acetylcholine to muscarinic receptors on airway smooth muscle. β 2 -agonists directly activate β 2 -adrenoreceptors, causing airway smooth muscle relaxation. Th erefore, by simultaneously addressing both mechanisms of bronchodilation, one can potentially modulate against the inter-patient and intrapatient variability in response to individual agents (49) . Th is should lead to a bronchodilator response which would not otherwise be seen if one or other agent were prescribed alone. Clinical studies have shown this potentially synergistic eff ect of co-prescribing, in which the combined treatment eff ect of LABA and LAMA is greater, or longer-lasting than expected from single agent bronchodilation. Th is may relate to M 3 -receptor blockade by LAMA amplifying and prolonging LABAinduced β 2 -adrenoreceptors activation (50) , and provides mechanistic support for the potential of LABA and LAMA inhaled combinations.
At least 12 randomised clinical trials have set out to investigate clinical outcomes after LABA and LAMA co-prescribing (formoterol, arformoterol, or indacaterol co-prescribed with tiotropium) (51) . Th e largest of these, INTRUST-1 and INTRUST-2 trials, randomised 1134 and 1142 patients with moderate to severe COPD respectively, already receiving open-label tiotropium 18 μg, to indacaterol 150 μg once-daily or placebo for 12 weeks (52) . Concurrent use of indacaterol plus tiotropium provided superior bronchodilation compared with tiotropium alone, increasing the FEV 1 AUC by 130 and 120 mL, trough by 80 and 70 mL (p < 0.001) and trough IC by 130 and 100 mL (p < 0.01). Importantly, the adverse event (AE) profi le was similar between treatments except cough, which was more common in the LABA plus LAMA patients. Meta-analysis of eight randomised trials of tiotropium plus formoterol, compared with tiotropium alone, including 1868 patients with stable COPD, found that treatment with tiotropium plus formoterol improved lung function (weighted mean diff erence in FEV 1 of 105 mL) and symptom scores (weighted mean diff erence in transitional dyspnoea index (TDI) of 1.5). However, there was no signifi cant reduction in exacerbations seen when compared to treatment with tiotropium alone (53) . Th ere was a trend towards a decrease in adverse events, although this was not statistically signifi cant.
LABA and LAMA fi xed-dose combinations
Th e development of a LABA/LAMA FDC is a simple way of ensuring that medication burden is reduced (single inhaler vs. multiple inhalers) thus minimising the risk of non-compliance. Th e challenge in the development of FDC inhalers is ensuring the balance between drug effi cacy and side eff ect profi le. Th is includes determining the minimally eff ective doses of LABA's and LAMA's in combination preparations, accepting that they may not be the same as in monotherapy preparations due to combination pharmacodynamics.
A number of LABA/LAMA FDC are currently in clinical development (Table 2) . One combination, known as QVA149 (Ultibro®, Novartis), a FDC of indacaterol (110 μg) and glycopyrronium (50 μg), is the fi rst once-daily dual agent bronchodilators to be approved for clinical use in Europe. Th e FDC of a LAMA, umeclidinium (UMEC), and a LABA, vilanterol (VI) (62.5/25 μg), known as UMEC/VI (Anoro, GlaxoSmithKline), was approved by the FDA in December 2013, by the EMA in May, 2014 and in Japan in July, 2014. In a recent study, the use of once-daily UMEC/VI FDC over 24 weeks resulted in signifi cant improvements of trough FEV 1 when compared to placebo as well as monotherapy of the individual components (54) .
In Phase II studies, QVA149 showed a fast onset of action with a statistically signifi cant (p < 0.0001) increase in FEV 1 over placebo, indacaterol (300 μg and 600 μg) 5 minutes post-dose on day 1 and a signifi cant (p < 0.05) increase in FEV 1 over placebo, indacaterol (300 μg and 600 μg) at all time-points on day 1 (55) . In a cardiovascular safety-orientated trial, QVA149 was well tolerated with an acceptable AE profi le (56). QVA149 is being investigated in a large ongoing, Phase III programme called IGNITE comprising 11 studies of more than 10,000 patients. One trial (ILLU-MINATE) compared QVA149 with SFC in 523 patients with no history of exacerbations within the preceding year in a double-blind, double-dummy, parallel-group design (40) . QVA149 provided signifi cantly better, clinically relevant improvements in lung function with a rapid onset of action; at 26 weeks, FEV 1 AUC 0-12h was signifi cantly higher with QVA149, with a treatment difference of 0·138 L (p < 0·0001 versus SFC) (see Figure 1) . Signifi cant improvements in TDI scores, with a treatment diff erence of 0.76 (p = 0.003 versus SFC), and reduced use of rescue medication was also seen with QVA149. Th e study design allowed insights into the impact of ICS withdrawal-at Week 26 patients who had been on ICS therapy at enrollment showed similarly higher values for FEV 1 with QVA149 compared with SFC to those who had not been on ICS treatment. Th is study supports the approach of using one or more bronchodilators for symptomatic COPD at low risk of exacerbation without ICS.
Conclusion
Th e role of ICS in the treatment paradigm for COPD is changing. Th is is driven by the growing evidence of increased risk of pneumonia, and a new class of LABA/ LAMA FDC which simplifi es dual bronchodilation, presenting a plausible alternative for some patients. As the evidence base for dual bronchodilation expands, it is likely that maximal bronchodilation will move up the treatment algorithm, with ICS reserved for those with more severe disease who are not controlled on dual therapy or where the clinical phenotype is known to receive therapeutic benefi t. Th is change has already manifested in some COPD algorithms, such as those at Tayside, representing a signifi cant change in recommended prescribing practice. Co-prescribing of LABA and LAMA is utilised much less frequently than LAMA monotherapy, ICS/LABA combinations, and the triple combination of LAMA plus ICS/LABA in recent reviews of prescribing practice (12) .
Th e key issue is the balance of risk-benefi t of ICS in individual patients; the risk of pneumonia versus the benefi t of reduced exacerbations. With the availability of new FDC, dual bronchodilation can be prescribed without increasing the dose of the LABA or LAMA component, and delivered in a simple, once-daily dosing regimen as a single inhaler. Th e once-daily dosing may be quite important for COPD patients, with evidence suggesting that compliance and adherence to treatment plans is historically poor, with COPD patients particularly vulnerable to treatment adherence lapses (57) . However, further data of the equivalence of LABA/ LAMA with ICS/LABA in respect to exacerbation frequency is required.
For those patients already receiving ICS, the key concern is the risk of precipitating an exacerbation by ICS cessation, therefore careful review and individualised patient management is required. A patient's response to treatment, their preference, the likely side eff ects, the risk of exacerbation and fi nancial cost implications require consideration. However for those patients with FEV 1 > 50% without frequent exacerbations, it is likely that the risk-benefi t is in favour of considering stopping ICS treatment. ICS withdrawal may be associated with worsening of COPD control so must be done carefully (58) . For those patients with the most advanced disease, triple therapy will remain the preferred treatment. Th e optimal posology of triple drug treatment requires further consideration, with the likely scenario of LABA/ LAMA FDC co-prescribed with an ICS in a single inhaler emerging as the preferred option.
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